The cancer-associated meprin β variant G32R provides an additional activation site and promotes cancer cell invasion.


Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
31 05 2019
Historique:
received: 23 05 2018
accepted: 23 04 2019
pubmed: 12 5 2019
medline: 1 7 2020
entrez: 12 5 2019
Statut: epublish

Résumé

The extracellular metalloprotease meprin β is expressed as a homodimer and is primarily membrane bound. Meprin β can be released from the cell surface by its known sheddases ADAM10 and ADAM17. Activation of pro-meprin β at the cell surface prevents its shedding, thereby stabilizing its proteolytic activity at the plasma membrane. We show that a single amino acid exchange variant (G32R) of meprin β, identified in endometrium cancer, is more active against a peptide substrate and the IL-6 receptor than wild-type meprin β. We demonstrate that the change to an arginine residue at position 32 represents an additional activation site used by furin-like proteases in the Golgi, which consequently leads to reduced shedding by ADAM17. We investigated this meprin β G32R variant to assess cell proliferation, invasion through a collagen IV matrix and outgrowth from tumor spheroids. We found that increased meprin β G32R activity at the cell surface reduces cell proliferation, but increases cell invasion.

Identifiants

pubmed: 31076514
pii: jcs.220665
doi: 10.1242/jcs.220665
pii:
doi:

Substances chimiques

Interleukin-6 0
Membrane Proteins 0
Collagen 9007-34-5
Amyloid Precursor Protein Secretases EC 3.4.-
Metalloendopeptidases EC 3.4.24.-
meprin A EC 3.4.24.18
ADAM10 Protein EC 3.4.24.81
ADAM10 protein, human EC 3.4.24.81
ADAM17 Protein EC 3.4.24.86
ADAM17 protein, human EC 3.4.24.86

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2019. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare no competing or financial interests.

Auteurs

Henning Schäffler (H)

Biochemical Institute, Otto-Hahn Platz 9, 24118 Kiel, Germany.

Wenjia Li (W)

Anatomical Institute, Otto-Hahn Platz 8, 24118 Kiel, Germany.

Ole Helm (O)

Institute for Experimental Cancer Research, Arnold-Heller-Str. 3, 24105 Kiel, Germany.

Sandra Krüger (S)

Dept. of Pathology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Arnold-Heller-Str. 3/14, 24105 Kiel, Germany.

Christine Böger (C)

Dept. of Pathology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Arnold-Heller-Str. 3/14, 24105 Kiel, Germany.

Florian Peters (F)

Biochemical Institute, Otto-Hahn Platz 9, 24118 Kiel, Germany.

Christoph Röcken (C)

Dept. of Pathology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Arnold-Heller-Str. 3/14, 24105 Kiel, Germany.

Susanne Sebens (S)

Institute for Experimental Cancer Research, Arnold-Heller-Str. 3, 24105 Kiel, Germany.

Ralph Lucius (R)

Anatomical Institute, Otto-Hahn Platz 8, 24118 Kiel, Germany.

Christoph Becker-Pauly (C)

Biochemical Institute, Otto-Hahn Platz 9, 24118 Kiel, Germany.

Philipp Arnold (P)

Anatomical Institute, Otto-Hahn Platz 8, 24118 Kiel, Germany p.arnold@anat.uni-kiel.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH